Back to Search
Start Over
Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
- Source :
-
Pharmacogenomics [Pharmacogenomics] 2018 Jan; Vol. 19 (1), pp. 7-16. Date of Electronic Publication: 2017 Dec 01. - Publication Year :
- 2018
-
Abstract
- Aim: This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab.<br />Materials & Methods: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis.<br />Results: Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months.<br />Conclusion: Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.
- Subjects :
- Adult
Biomarkers metabolism
Female
Humans
Male
Multivariate Analysis
Pharmacogenetics methods
Polymorphism, Single Nucleotide genetics
Prospective Studies
Adalimumab therapeutic use
Anti-Inflammatory Agents therapeutic use
Dermatologic Agents therapeutic use
Infliximab therapeutic use
Psoriasis drug therapy
Psoriasis genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8042
- Volume :
- 19
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Pharmacogenomics
- Publication Type :
- Academic Journal
- Accession number :
- 29192552
- Full Text :
- https://doi.org/10.2217/pgs-2017-0143